Table 1 Pairwise meta-analysis results of different outcomes in studies unable to merge
0 | Outc1ome | No. | Treat 1 | Treat 2 | Mean Difference(95% Crl) |
|---|---|---|---|---|---|
I | 6MWT | 1 | laronidase_0.58Â mg/kg_QW | placebo | 38.1(10.10,66.10) |
FVC | 1 | laronidase_0.58Â mg/kg_QW | placebo | 5.6(2.40,8.80) | |
uGAG | 2 | pentosan_polysulphate_2mg/kg_QW | pentosan polysulphate_1mg/kg_QW | -2.66(-3.86,-1.46) | |
II | Liver V | 9 | pabinafusp_alfa_4.0Â mg/kg | pabinafusp_alfa_2.0Â mg/kg | -13.3(-24.3,-2.3) |
VI | uGAG | 20 | galsulfase + odiparcil_1000 mg/day | galsulfase + placebo | 1636.3(1006.3,2266.3) |
20 | galsulfase + odiparcil_500 mg/day | galsulfase + placebo | 545.4(365.4,725.4) | ||
20 | odiparcil_1000 mg/day | galsulfase + placebo | 1413.4(453.4,2373.4) | ||
21 | rhASB | placebo | -217(-258,-176) | ||
23 | galsulfase_1.0Â mg/kg_QW | galsulfase_2.0Â mg/kg_QW | -286.5(-436.5,-136.5) | ||
6MWT | 20 | galsulfase + odiparcil_1000 mg/day | galsulfase + placebo | -75(-151,1) | |
20 | galsulfase + odiparcil_500 mg/day | galsulfase + placebo | -27.67(-106.67,51.33) | ||
20 | odiparcil_1000 mg/day | galsulfase + placebo | -30.5(-108.5,47.5) | ||
22 | rhASB_0.2Â mg/kg | rhASB_1.0Â mg/kg | 5(-78,88) | ||
VI | FVC | 20 | galsulfase + odiparcil_1000 mg/day | galsulfase + placebo | 0.12(0.021,0.219) |
20 | galsulfase + odiparcil_500 mg/day | galsulfase + placebo galsulfase + placebo | 0.13(0.031,0.229) | ||
20 | odiparcil_1000 mg/day | placebo | 0.13(0.01,0.25) | ||
21 | rhASB | galsulfase + placebo | -0.01(-0.029,0.129) | ||
MVV | 20 | galsulfase + odiparcil_1000 mg/day | galsulfase + placebo | 3.9(2.5,5.3) | |
20 | galsulfase + odiparcil_500 mg/day | galsulfase + placebo | 8.9(-16.1,33.9) | ||
21 | rhASB | placebo | 1.9(-1,4.8) |